Latest Articles about VVUS

ARNA Sheds Light on Belviq Launch - Analyst Blog

Zacks Equity Research — Fri, 10 May 2013 00:24:33 Z

Arena Pharmaceuticals Inc. ( ARNA ) recently announced that the US Drug Enforcement Administration (DEA) has assigned its obesity drug Belviq into Schedule IV of the Controlled Substances

Benzinga Market Primer: Wednesday, May 8

Matthew Kanterman — Wed, 08 May 2013 14:27:11 Z

Futures Flat On Strong Chinese Trade Data U.S. equity futures traded flat in early pre-market trade despite China reporting a rise in its trade balance in April. China reported that its trade

CHMP Backs VIVUS' Spedra - Analyst Blog

Zacks Equity Research — Wed, 01 May 2013 00:48:16 Z

VIVUS, Inc. ( VVUS ) recently announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its drug, Spedra

Merck Likely to Beat 1Q Earnings - Analyst Blog

Zacks Equity Research — Tue, 30 Apr 2013 00:50:44 Z

We expect Merck & Co. Inc. ( MRK ) to beat earnings expectations when it reports first-quarter 2013 results before the opening bell on May 1, 2013. Why a Likely Positive Surprise?

Pfizer Likely to Report In Line Earnings - Analyst Blog

Zacks Equity Research — Tue, 30 Apr 2013 00:50:14 Z

We expect Pfizer ( PFE ) to report in line first-quarter 2013 results before the opening bell on Apr 30, 2013. Factors at Play for 1Q We expect Pfizer to struggle to post meaningful

Will Eli Lilly Beat Earnings in 1Q? - Analyst Blog

Zacks Equity Research — Wed, 24 Apr 2013 01:11:25 Z

We expect Eli Lilly and Company ( LLY ) to beat earnings expectations when it reports first-quarter 2013 results before the opening bell on Apr 24, 2013. Why a Likely Positive Surprise?

Will Amgen Beat Earnings? - Analyst Blog

Zacks Equity Research — Tue, 23 Apr 2013 01:11:30 Z

We expect Amgen Inc. ( AMGN ) to beat earnings expectations when it reports first-quarter 2013 results after the closing bell on Apr 23, 2013. Why a Likely Positive Surprise? Our

Forest Labs Likely to Miss 4Q Earnings - Analyst Blog

Zacks Equity Research — Mon, 22 Apr 2013 20:11:44 Z

We expect Forest Laboratories Inc. ( FRX ) to miss earnings expectations when it reports fourth-quarter fiscal 2013 results on Apr 23, before the opening bell. Forest Labs' fiscal year ends

Expanded Access for VIVUS' Qsymia - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 03:10:09 Z

VIVUS, Inc. ( VVUS ) recently announced that the amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) of its obesity drug, Qsymia (phentermine and topiramate

Vivus Sees a Rare Jump in Near-Term Call Volume

Schaeffer's Investment Research — Thu, 18 Apr 2013 00:20:00 Z

Vivus ( VVUS ) was trending higher on Tuesday, after the Food and Drug Administration (FDA) granted the firm approval to sell its weight-loss drug, Qsymia, in retail pharmacies. As a result,

ARNA/Eisai's Belviq Filed in Mexico - Analyst Blog

Zacks Equity Research — Thu, 04 Apr 2013 00:19:58 Z

Arena Pharmaceuticals, Inc. ( ARNA ) recently announced that Eisai Laboratories S. de R.L. de C.V, a subsidiary of Eisai Inc., has submitted a marketing authorization application (MAA) for

Vivus Opts for Royalty Financing - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 03:21:59 Z

Vivus, Inc. ( VVUS ) recently announced that it has entered into an agreement with a Pharmakon Advisors managed investment fund for a $110 million non-equity financing. Vivus will initially

Loss at OREX Narrower than Expected - Analyst Blog

Mark Vickery — Fri, 15 Mar 2013 01:45:16 Z

Orexigen Therapeutics, Inc. ( OREX ) reported a net loss of 41 cents per share in the fourth quarter of 2012, much wider than the year-ago loss of 9 cents but 4 cents narrower than the

Arena Cuts Loss, Misses Estimates - Analyst Blog

Zacks Equity Research — Sat, 09 Mar 2013 00:43:01 Z

Arena Pharmaceuticals Inc.'s ( ARNA ) loss (excluding special items) of 10 cents per share in the fourth quarter of 2012 was narrower than the year-ago loss of 16 cents per share. The

Vivus Reports Wider Loss - Analyst Blog

Zacks Equity Research — Tue, 26 Feb 2013 23:54:01 Z

Vivus Inc. 's ( VVUS ) fourth quarter 2012 loss of 56 cents per share was wider than the Zacks Consensus Estimate of a loss of 44 cents per share and the year-ago loss of 14 cents per